# Prellis Biologics

> Prellis Biologics is a Berkeley, California biotech that 3D-prints human lymph node organoids to grow real human antibodies in a dish. Its EXIS platform uses holographic two-photon laser bioprinting plus AI to recreate the human immune response in vitro, discovering fully human antibody therapeutics faster and cheaper than animal-based methods, including against difficult targets like GPCRs where mouse models fail.

- **Founded:** 2016
- **Headquarters:** Berkeley, California, United States
- **Founders:** Melanie Matheu (Founder & Chief Technology Officer (founding CEO))
- **Team size:** ~58 employees
- **Products:** EXIS™ Platform, LNO™ (Lymph Node Organoid)
- **Notable:** Built the first externalized human immune system (EXIS) for de novo therapeutic antibody discovery, Generated ~300 human antibodies targeting SARS-CoV-2 from printed tissue, Signed antibody discovery deals with Bristol Myers Squibb, Sanofi, and Eli Lilly

## Products & services

- **EXIS™ Platform** — Externalized human immune system for de novo antibody discovery. Recreates human immune biology in 3D-printed organoids, activates B cells, and uses AI to screen and optimize candidates, delivering fully human, low-immunogenicity antibodies with broad epitope coverage.
- **LNO™ (Lymph Node Organoid)** — Bioprinted lymph node organoid built with holographic two-photon laser bioprinting that recapitulates the biology of a human lymph node, enabling natural antibody production in vitro using human PBMCs from multiple donors.

## Achievements

- Built the first externalized human immune system (EXIS) for de novo therapeutic antibody discovery
- Generated ~300 human antibodies targeting SARS-CoV-2 from printed tissue
- Signed antibody discovery deals with Bristol Myers Squibb, Sanofi, and Eli Lilly
- Raised ~$65M total, including a $35M Series C in 2022
- Pioneered holographic two-photon laser bioprinting fine enough to print vascular and lymphatic tissue

## Latest updates

- **2023-11** — Most recent funding event on record (Series C era), with total funding around $65M.
- **2022-08** — Appointed Michael Nohaile, PhD as CEO; Melanie Matheu moved to CTO and retained a board seat; raised $35M Series C.
- **2022-03** — Announced antibody discovery collaboration with Sanofi.
- **2022-01** — Announced multi-target collaboration and license agreement with Bristol Myers Squibb.

## Links

- Website: https://prellisbio.com
- LinkedIn: https://www.linkedin.com/company/prellis-biologics
- Twitter/X: https://twitter.com/prellisbio
- Facebook: https://facebook.com/PrellisBio/

---

Profile page: https://yespress.io/prellis-biologics
Published by YesPress — https://yespress.io
Last updated: 2026-06-13